Overview
Switzerland medical device maker's FY 2025 revenue rose 18.5% in constant currency
Adjusted EBITDA grew 19.1% and margin advanced to 29.0% in constant currency
Net profit increased 31% yr/yr, including one-off gains from Parcus Medical acquisition
Outlook
Medacta targets 2026 revenue growth of 10% to 14% in constant currency
Company expects 2026 adjusted EBITDA margin to expand by around 50bps vs. prior year
Medacta sees mid-term revenue CAGR of 12% to 15% in constant currency through 2027
Result Drivers
INNOVATION & SALES FORCE - Co said revenue growth was driven by ongoing product innovation, expanded sales force, and medical education efforts
PRODUCT LINE GROWTH - Strong revenue growth in Knee, Hip, Extremities, and Spine segments, with Extremities up 46.2% in c.c.
MARGIN EXPANSION - Adjusted EBITDA margin improved due to efficiency gains and lower sales and marketing costs
Company press release: ID:nEQ8rcP4Ba
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Adjusted EBITDA
EUR 190.80 mln
FY Adjusted EBITDA Margin
29.00%
FY Adjusted Free Cash Flow
EUR 152.70 mln
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)